Raschi E, Antonazzo IC, La Placa M, Ardizzoni A, Poluzzi E, De Ponti F., Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System., «THE ONCOLOGIST», 2019, 24, pp. e1228 - e1231 [articolo]
Raschi E.; De Ponti F., Strategies for early prediction and timely recognition of drug-induced liver injury: The case of cyclin-dependent kinase 4/6 inhibitors, «FRONTIERS IN PHARMACOLOGY», 2019, 10, Article number: 1235, pp. 1 - 15 [articolo]Open Access
Raschi E.; Mazzarella A.; Antonazzo I.C.; Bendinelli N.; Forcesi E.; Tuccori M.; Moretti U.; Poluzzi E.; De Ponti F., Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System, «TARGETED ONCOLOGY», 2019, 14, pp. 205 - 221 [articolo]Open Access
Dothel, Giovanni; Barbaro, Maria Raffaella; Raschi, Emanuel; Barbara, Giovanni; De Ponti, Fabrizio*, Advancements in drug development for diarrhea-predominant irritable bowel syndrome, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2018, 27, pp. 251 - 263 [articolo]
Raschi, Emanuel*; Girardi, Anna; Poluzzi, Elisabetta; Forcesi, Emanuele; Menniti-Ippolito, Francesca; Mazzanti, Gabriela; De Ponti, Fabrizio, Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems, «DRUG SAFETY», 2018, 41, pp. 745 - 752 [articolo]
Raschi, Emanuel; Diemberger, Igor; Cosmi, Benilde; De Ponti, Fabrizio, ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations, «INTERNAL AND EMERGENCY MEDICINE», 2018, 13, pp. 1 - 9 [articolo]
Raschi E.; Diemberger I.; Cosmi B.; De Ponti F., ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations—authors’ reply, «INTERNAL AND EMERGENCY MEDICINE», 2018, 13, pp. 635 - 636 [replica/breve intervento]
Mouchet, Julie; Salvo, Francesco; Raschi, Emanuel; Poluzzi, Elisabetta; Antonazzo, Ippazio Cosimo; De Ponti, Fabrizio; Bégaud, Bernard, Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis, «VACCINE», 2018, 36, pp. 1548 - 1555 [articolo]
Mouchet, Julie; Salvo, Francesco; Raschi, Emanuel; Poluzzi, Elisabetta; Antonazzo, Ippazio Cosimo; De Ponti, Fabrizio; Bégaud, Bernard, Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis, «PHARMACOLOGICAL RESEARCH», 2018, 132, pp. 108 - 118 [articolo]
Antonazzo, Ippazio Cosimo; Raschi, Emanuel; Forcesi, Emanuele; Riise, Trond; Bjornevik, Kjetil; Baldin, Elisa; De Ponti, Fabrizio; Poluzzi, Elisabetta, Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System, «EXPERT OPINION ON DRUG SAFETY», 2018, 17, pp. 869 - 874 [articolo]
Mei, Riccardo; Raschi, Emanuel; Forcesi, Emanuele; Diemberger, Igor; De Ponti, Fabrizio; Poluzzi, Elisabetta, Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System, «INTERNATIONAL JOURNAL OF CARDIOLOGY», 2018, 273, pp. 183 - 186 [articolo]
Carnovale, Carla; Raschi, Emanuel; Leonardi, Luca; Moretti, Ugo; De Ponti, Fabrizio; Gentili, Marta; Pozzi, Marco; Clementi, Emilio; Poluzzi, Elisabetta; Radice, Sonia, No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase, «EXPERT REVIEW OF VACCINES», 2018, 17, pp. 363 - 381 [articolo]
Raschi, Emanuel*; Poluzzi, Elisabetta; Fadini, Gian Paolo; Marchesini, Giulio; De Ponti, Fabrizio, Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?, «DIABETES, OBESITY AND METABOLISM», 2018, 20, pp. 2711 - 2723 [articolo]Open Access
Raschi, Emanuel; Mazzotti, Arianna; Poluzzi, Elisabetta; De Ponti, Fabrizio; Marchesini, Giulio*, Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease, «EXPERT OPINION ON PHARMACOTHERAPY», 2018, 19, pp. 1903 - 1914 [articolo]
Raschi, E.; Poluzzi, E.*; Salvo, F.; Pariente, A.; De Ponti, F.; Marchesini, G.; Moretti, U., Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems, «NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES», 2018, 28, pp. 533 - 542 [articolo]
